National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Larotrectinib (Vitrakvi®) is indicated  for patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.

NCPE Assessment Process Ongoing
Rapid review commissioned 20/11/2019
Rapid review completed 13/01/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of larotrectinib compared with the current standard of care.